Federal regulators have denied Johnson & Johnson's request to expand approval of its blood thinner Xarelto for a new use to prevent life-threatening blood clots in high-risk patients.
A majority of Food and Drug Administration panelists have voted against a new use for Johnson & Johnson's blood thinner Xarelto to reduce life-threatening blood clots.